ArticleRMD open2026
Arrhythmic risk stratification in psoriatic arthritis: a retrospective, electrogram-based comparative analysis.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriatic arthritis (PsA) is a chronic inflammatory systemic disease that is associated with cardiovascular comorbidities, particularly with an increased risk of arrhythmias. Despite the evidence, a structured population-based risk stratification that relates ECG parameters to clinical characteristics in PsA is still lacking.
methodsData from patients diagnosed with PsA who presented to our centre between 2014 and 2022 as well as from an age-matched and sex-matched control group of cardiovascular patients were collected. A variety of established ECG parameters associated with atrial and ventricular repolarisation and atrioventricular conduction as well as a comprehensive set of clinical variables were evaluated.
resultsA total of 725 patients with PsA alongside 725 matched cardiovascular patients were enrolled (mean age 52.5±13.4 years). The median duration of PsA was 2 years. Patients with PsA had similar rates of first-degree atrioventricular block (AVB I°) with the control group (9.5% vs 10.2%; p=0.725). After excluding patients with known atrial arrhythmias, patients with PsA had higher rates of significant P-wave terminal force in V1 versus controls (30.2% vs 14.1%; p<0.001). Furthermore, patients with PsA had a longer corrected Tpeak-Tend interval (0.26±0.04 vs 0.23±0.05; p<0.001). After adjusting for age, among patients with PsA, male sex (16.4% vs 7.1%; p=0.006) as well as long disease duration (18.0% vs 6.9%; p<0.001) were associated with AVB I°.
conclusionPatients with PsA are at a significantly increased risk for ECG abnormalities related to both atrial and ventricular repolarisation as well as atrioventricular conduction. Non-invasive, ECG-based tools for structured risk stratification could facilitate the early detection of patients at risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.